Pfizer Market Cap 2010-2024 | PFE

Pfizer market cap history and chart from 2010 to 2024. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Pfizer market cap as of January 31, 2025 is $150.86B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $150.855B $58.496B
Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $763.326B 79.06
Novo Nordisk (NVO) Denmark $377.087B 27.19
Johnson & Johnson (JNJ) United States $363.912B 15.13
AbbVie (ABBV) United States $309.709B 16.30
Merck (MRK) United States $248.613B 16.52
Roche Holding AG (RHHBY) Switzerland $247.847B 0.00
AstraZeneca (AZN) United Kingdom $217.852B 18.54
Novartis AG (NVS) Switzerland $210.389B 13.98
Sanofi (SNY) $132.349B 11.99
Bayer (BAYRY) Germany $22.242B 3.56
Innoviva (INVA) United States $1.183B 9.84